Expert Opinion on Investigational Drugs

Article	Citations
Navafenterol for chronic obstructive pulmonary disease therapy	101
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?	80
Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials	76
Novel experimental and early investigational drugs for the treatment of bipolar disorder	74
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	73
Investigational drugs for HIV: trends, opportunities and key players	69
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	62
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	58
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia	55
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma	52
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized stu	50
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a nov	49
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities	49
Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus	42
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	41
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	40
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	40
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	36
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	32
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	32
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	31
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	31
Lessons learned from early-stage clinical trials for diabetic nephropathy	30
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights	26
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia	26

Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	26
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies	25
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022	25
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development	22
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?	22
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities	21
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	21
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis	20
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	20
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	20
Experimental drugs for the prevention or treatment of sensorineural hearing loss	20
Theranostic strategies in sarcoma: preliminary clinical evidence	19
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	19
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development	19
Investigational drugs for the treatment of olfactory dysfunction	19
Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years	18
Fibroblast growth factor therapies in biliary tract cancers: current and future state	18
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma	17
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials	17
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease	17
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?	17
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development	16
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	15
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	15
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	15
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	14
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma	14
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	14
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers	14
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	14
Therapies in preclinical and clinical development for Angelman syndrome	14
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	14
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	14
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	14
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	13
Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver	13
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer’s disease	13
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	12
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	12
Low-dose aspirin for early COVID-19: does the early bird catch the worm?	12
Anti-diabetic drugs and NASH: from current options to promising perspectives	12
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	12
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	11
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	11
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	11
Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases	11
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	11
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	10
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	10
Atezolizumab: an investigational agent for the treatment of biliary tract cancer	10

Immunotherapeutic strategies for treating opioid use disorder and overdose	10
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis	10
Interleukin antagonists for atopic dermatitis: a new era of therapy	10
Psoriasis: a focus on upcoming oral formulations	10
Investigational drugs for the treatment of scleroderma: what’s new?	10
JAK inhibitors for rheumatoid arthritis	10
Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?	10
Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what’s new?	10
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers	10
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	9
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond	9
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	9
Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis	9
Epigenetic regulation of radioresistance: insights from preclinical and clinical studies	9
Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma	9
Neuropathic pain management: a focused review of current treatments and novel data from main ongoing clinical trials	9
Collocation of metformin and dipeptidyl peptidase-4 inhibitor is associated with increased risk of diabetes-related vascular dementia: A single hospital study in Northern Taiwan	9
Investigational drugs in clinical trials for macular degeneration	9
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	8
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	8
Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?	8
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data	8
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	8
JAK inhibitors in crohn’s disease: ready to go?	8
Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review	8
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	8
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	8
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	8
The role of phosphodiesterase 9A inhibitors in heart failure	8
Investigational bispecific antibodies for the treatment of rheumatoid arthritis	8
‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’	8
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials	7
Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata	7
Correction	7
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	7
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	7
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications	7
Radiotherapy-induced severe oral mucositis: pharmacotherapies in recent and current clinical trials	7
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers	7
Fezolinetant in the treatment of vasomotor symptoms associated with menopause	7
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	7
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?	7
FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential	7
Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial	7
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials	6
Investigational treatment strategies in glioblastoma: progress made and barriers to success	6
HPV-induced cancers: preclinical therapeutic advancements	6
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer	6
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential	6
Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?	6
The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects	6
Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms	6
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis	6
Current emerging and investigational drugs for the treatment of chronic hand eczema	6
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	6
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	6
Developments and challenges for new and emergent preparations for male hypogonadism treatment	6
Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials	6
Retatrutide: a triple incretin receptor agonist for obesity management	6
Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials	5
The challenges of combinatory immunotherapy for biliary tract cancer	5
Nanocrystalline gold (CNM-Au8): a novel bioenergetic treatment for ALS	5
Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents	5
Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs	5
Immune-based therapies in diffuse large B-cell lymphoma	5
Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients	5
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	5
Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes	5
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials	5
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	5
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	5
Sodium/bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis	5
Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study	5
Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review	5
CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS)	5
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	5
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials	5
An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions	5
Model Informed Development of SIM0295 in Patients with Gout and Hyperuricemia and Healthy Volunteers Using a Population Pharmacokinetics/ Pharmacodynamics Approach	5
Medical treatments for abdominal aortic aneurysm: an overview of clinical trials	5

Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	5
Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition	5
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	5
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	5
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	5
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	5
Investigational drugs inhibiting complement for the treatment of geographic atrophy	5
Role of bromodomain and extraterminal (BET) proteins in prostate cancer	4
RNA therapeutics for mood disorders: current evidence toward clinical trials	4
Tumor immunology and immunotherapy for endometrial cancer	4
Potassium channel modulators and schizophrenia: an overview of investigational drugs	4
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	4
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects	4
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	4
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?	4
COVID-related fibrosis: insights into potential drug targets	4
Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond	4
Emerging agents for the treatment and prevention of stroke: progress in clinical trials	4
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	4
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action	4
Camrelizumab: an investigational agent for hepatocellular carcinoma	4
Recent developments for new investigational JAK inhibitors in psoriatic arthritis	4
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?	4
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	4
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	4
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?	4
Emerging treatments for chronic urticaria	4
Advances in targeting estrogen synthesis and receptors in patients with endometriosis	4
Investigational new drugs for the treatment of Dravet syndrome: an update	4
Anti-inflammatory therapies for acute respiratory distress syndrome	4
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	4
Investigational systemic drugs for moderate to severe plaque psoriasis: What’s new?	4
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	4
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	3
Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu	3
Inflammation and Huntington’s disease – a neglected therapeutic target?	3
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	3
A focused report on IFN-1 targeted therapies for lupus erythematosus	3
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	3
Upamostat: a serine protease inhibitor for antiviral, gastrointestinal, and anticancer indications	3
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	3
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	3
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclini	3
Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress	3
Monoclonal antibody therapies in the management of SARS-CoV-2 infection	3
Investigational drugs for the treatment of dysmenorrhea	3
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers	3
Innate immunity as a target for novel therapeutics in triple negative breast cancer	3
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase	3
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics	3
Early investigational agents for the treatment of rosacea: drugs in phase I and II clinical development	3
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	3
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	3
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines	3
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential	3
Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia	3
Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects	3
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	3
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	3
Assessing potential of psilocybin for depressive disorders	3
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	3